Home

EDWARD PENHOET

CIK 1198332 · last filed 2019-04-04

EDWARD PENHOET is a corporate insider who has filed 33 SEC Form 4 insider transactions across 7 companies since 2007. Across all open-market trades the lifetime net is +$482.5K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $613.7M across reported positions. 20 SEC filings were submitted jointly with ALTA BIOPHARMA PARTNERS III LP.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$613.70M

Companies

7

Total Filings

33

Lifetime Open-Market Net

$482.5K

Filer Profile

Reported Address
ONE EMBARCADERO CENTER SUITE 3700
SAN FRANCISCO, CA 94111
Related Filers
ALTA BIOPHARMA PARTNERS III LP — 20 joint filings, latest 2014-02-05
FARAH CHAMPSI — 20 joint filings, latest 2014-02-05
ALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KG — 16 joint filings, latest 2014-02-05
ALTA EMBARCADERO BIOPHARMA PARTNERS III LLC — 16 joint filings, latest 2014-02-05
EDWARD HURWITZ — 16 joint filings, latest 2014-02-05
JEAN DELEAGE — 13 joint filings, latest 2010-10-27
ALIX MARDUEL — 7 joint filings, latest 2009-04-07
GARRETT GRUENER — 4 joint filings, latest 2007-01-09
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
SCYX Director — $4.39 — $0 1 2015-06-05
CymaBay Therapeutics, Inc. (CBAY) Delisted Director — $32.48 — $0 1 2015-01-08
CCXI Director 114,910 $12.05 $1.38M $0 3 2013-05-24
ZYMOGENETICS INC (ZGEN) Delisted Director 0 $12.01 $0 $0 6 2010-10-12
CORT Director 5,525,313 $110.82 $612.32M $482.5K 5 2010-04-06
IDM PHARMA, INC. (IDMI) Delisted Director 1,829 — — $0 4 2008-06-26
RENOVIS INC (RNVS) Delisted Director 79,028 — — $0 2 2007-05-16

Recent Filings

33 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2019-04-04 — Disp (D) — $0
2019-01-07 — Grant (A) — $0
2018-01-08 — Grant (A) — $0
2017-01-06 — Grant (A) — $0
2016-01-06 — Grant (A) — $0
2015-06-05 SCYX Grant (A) — $0 EDGAR
2015-01-09 — Grant (A) — $0
2015-01-08 CymaBay Therapeutics, Inc. (CBAY) Delisted Grant (A) — $0 EDGAR
2014-07-31 — Mixed +2,482,775 $3.59M
2014-01-15 — Grant (A) — $0
Showing 1–10 of 33
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.